About AbbVie (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Industry, Sector and Symbol
Industry Specialty & Advanced Pharmaceuticals
Trailing P/E Ratio24.3543689320388
Forward P/E Ratio18.11
Sales & Book Value
Annual Sales$25.64 billion
Price / Sales6.25
Cash Flow$5.60 per share
Price / Cash17.93
Book Value$2.85 per share
Price / Book35.21
Net Income$5.95 billion
Return on Equity153.80%
Return on Assets12.83%
AbbVie (NYSE:ABBV) Frequently Asked Questions
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie declared a quarterly dividend on Friday, October 27th. Shareholders of record on Friday, January 12th will be given a dividend of $0.71 per share on Thursday, February 15th. This represents a $2.84 annualized dividend and a yield of 2.83%. The ex-dividend date is Thursday, January 11th. This is a boost from AbbVie's previous quarterly dividend of $0.64. View AbbVie's Dividend History.
How will AbbVie's stock buyback program work?
AbbVie declared that its Board of Directors has approved a stock repurchase program on Sunday, April 9th 2017, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 5% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's board of directors believes its stock is undervalued.
How were AbbVie's earnings last quarter?
AbbVie Inc (NYSE:ABBV) posted its earnings results on Friday, October, 27th. The company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.39 by $0.02. The business earned $7 billion during the quarter, compared to analyst estimates of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business's revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.21 EPS. View AbbVie's Earnings History.
When will AbbVie make its next earnings announcement?
What guidance has AbbVie issued on next quarter's earnings?
AbbVie updated its FY18 earnings guidance on Friday, October, 27th. The company provided earnings per share (EPS) guidance of $6.37-6.57 for the period, compared to the Thomson Reuters consensus estimate of $6.59. AbbVie also updated its FY17 guidance to $5.53-5.55 EPS.
Where is AbbVie's stock going? Where will AbbVie's stock price be in 2018?
14 equities research analysts have issued 12 month price targets for AbbVie's shares. Their forecasts range from $84.00 to $120.00. On average, they anticipate AbbVie's stock price to reach $100.15 in the next year. View Analyst Ratings for AbbVie.
What are Wall Street analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares outperformed the industry in 2017 supported by a series of positive news including promising data from several pivotal studies, regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settlement of its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition. Estimates have remained stable ahead of the Q4 earnings release. AbbVie has a positive record of earnings surprises in the recent quarters." (1/5/2018)
- 2. UBS Group AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
- 3. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
Who are some of AbbVie's key competitors?
Some companies that are related to AbbVie include Salix Pharmaceuticals (SLXP), ConvaTec Group (CTEC), Advanced Accelerator Application (AAAP), Indivior (INDV), Supernus Pharmaceuticals (SUPN), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), Repligen (RGEN), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), Novan (NOVN), CorMedix (CRMD), Macrocure (MCUR), DARA Biosciences (DARA), Check Cap (CHEK) and Omthera Pharmaceuticals (OMTH).
Who are AbbVie's key executives?
AbbVie's management team includes the folowing people:
- Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer (Age 63)
- William J. Chase, Executive Vice President, Chief Financial Officer (Age 49)
- Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer (Age 51)
- Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary (Age 53)
- Carlos Alban, Executive Vice President - Commercial Operations (Age 54)
- Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer (Age 44)
- Timothy J. Richmond, Senior Vice President - Human Resources (Age 50)
- Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations (Age 53)
- Robert A. Michael, Vice President, Controller (Age 46)
- Robert J. Alpern M.D., Independent Director (Age 66)
Who owns AbbVie stock?
AbbVie's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.03%), Sit Investment Associates Inc. (0.03%), KAMES CAPITAL plc (0.02%), CHURCHILL MANAGEMENT Corp (0.02%), Exxonmobil Investment Management Inc. TX (0.02%) and Franklin Street Advisors Inc. NC (0.01%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.
Who sold AbbVie stock? Who is selling AbbVie stock?
AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Exxonmobil Investment Management Inc. TX, Fulton Bank N.A., Chesley Taft & Associates LLC, Accurate Investment Solutions Inc., CHURCHILL MANAGEMENT Corp, Franklin Street Advisors Inc. NC, Bogart Wealth LLC and Private Capital Advisors Inc.. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.
Who bought AbbVie stock? Who is buying AbbVie stock?
AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including Broadleaf Partners LLC, Sawyer & Company Inc, Montrusco Bolton Investments Inc., Bristol Advisors LLC, Tandem Investment Advisors Inc., Nisa Investment Advisors LLC, KCS Wealth Advisory and Atalanta Sosnoff Capital LLC. View Insider Buying and Selling for AbbVie.
How do I buy AbbVie stock?
Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AbbVie's stock price today?
One share of AbbVie stock can currently be purchased for approximately $100.34.
How big of a company is AbbVie?
AbbVie has a market capitalization of $159.95 billion and generates $25.64 billion in revenue each year. The company earns $5.95 billion in net income (profit) each year or $4.12 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.
How can I contact AbbVie?
AbbVie's mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The company can be reached via phone at +1-847-9327900.
MarketBeat Community Rating for AbbVie (ABBV)MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
AbbVie (NYSE:ABBV) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.64||2.64||2.63||2.54|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
7 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$100.15||$99.77||$93.33||$74.58|
|Price Target Upside: ||1.18% upside||4.57% upside||2.94% upside||2.49% upside|
AbbVie (NYSE:ABBV) Consensus Price Target History
AbbVie (NYSE:ABBV) Analyst Ratings History
(Data available from 1/16/2016 forward)
AbbVie (NYSE:ABBV) Earnings History and Estimates Chart
AbbVie (NYSE ABBV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/27/2017||Q3 2017||$1.39||$1.41||$7.00 billion||$7.00 billion||View||N/A|
|7/28/2017||Q2 2017||$1.40||$1.42||$6.93 billion||$6.94 billion||View||N/A|
|4/27/2017||Q1 2017||$1.26||$1.28||$6.49 billion||$6.54 billion||View||N/A|
|1/27/2017||Q416||$1.20||$1.20||$6.92 billion||$6.78 billion||View||Listen|
|10/28/2016||Q316||$1.21||$1.21||$6.55 billion||$6.43 billion||View||Listen|
|7/29/2016||Q216||$1.20||$1.26||$6.20 billion||$6.43 billion||View||Listen|
|4/28/2016||Q116||$1.14||$1.15||$6.03 billion||$5.96 billion||View||Listen|
|1/29/2016||Q415||$1.12||$1.13||$6.41 billion||$6.36 billion||View||Listen|
|10/30/2015||Q315||$1.08||$1.13||$5.90 billion||$4.94 billion||View||Listen|
|7/24/2015||Q215||$1.06||$1.08||$5.60 billion||$5.48 billion||View||Listen|
|4/23/2015||Q115||$0.85||$0.94||$718.50 million||$5.04 billion||View||Listen|
|1/30/2015||Q414||$0.86||$0.89||$5.34 billion||$5.45 billion||View||Listen|
|10/31/2014||Q3||$0.77||$0.89||$4.82 million||$5.02 million||View||Listen|
|7/25/2014||Q214||$0.76||$0.82||$4.70 billion||$4.93 billion||View||Listen|
|4/25/2014||Q114||$0.68||$0.71||$4.33 billion||$4.56 billion||View||Listen|
|1/31/2014||Q413||$0.82||$0.82||$5.10 billion||$5.11 billion||View||Listen|
|10/25/2013||Q313||$0.78||$0.82||$4.52 billion||$4.66 billion||View||Listen|
|7/26/2013||Q2 2013||$0.79||$0.92||$4.54 billion||$4.69 billion||View||Listen|
|4/26/2013||Q1 2013||$0.67||$0.68||$4.17 billion||$4.33 billion||View||Listen|
AbbVie (NYSE:ABBV) Earnings Estimates
2018 EPS Consensus Estimate: $6.99
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
AbbVie (NYSE:ABBV) Dividend Information
|Dividend Growth:||15.50% (3 Year Average)|
|Payout Ratio:||68.93% (Trailing 12 Months of Earnings) |
51.26% (Based on This Year's Estimates)
43.83% (Based on Next Year's Estimates)
|Track Record:||45 Years of Consecutive Dividend Growth|
AbbVie (NYSE:ABBV) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.19%
AbbVie (NYSE ABBV) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/18/2017||Timothy J Richmond||SVP||Sell||87,040||$98.45||$8,569,088.00||113,118|| |
|12/15/2017||Laura J Schumacher||Insider||Sell||145,510||$96.71||$14,072,272.10|| |
|11/21/2017||Richard A Gonzalez||Chairman||Sell||218,193||$94.01||$20,512,323.93||492,030|| |
|11/10/2017||Michael Severino||EVP||Sell||25,633||$94.69||$2,427,188.77||114,922|| |
|10/30/2017||Henry O Gosebruch||Insider||Sell||18,300||$90.55||$1,657,065.00||81,287|| |
|9/28/2017||Robert A Michael||VP||Sell||6,699||$88.00||$589,512.00||10,007|| |
|9/11/2017||Azita Saleki-Gerhardt||SVP||Sell||8,300||$85.02||$705,666.00||93,099|| |
|8/7/2017||Richard A Gonzalez||Chairman||Sell||193,131||$71.00||$13,712,301.00||469,623|| |
|8/4/2017||Richard A Gonzalez||Chairman||Sell||87,899||$71.02||$6,242,586.98||342,353|| |
|8/3/2017||Richard A Gonzalez||CEO||Sell||65,861||$71.00||$4,676,131.00||342,353|| |
|7/31/2017||Edward J Rapp||Director||Buy||4,000||$70.45||$281,800.00||15,498|| |
|7/31/2017||Henry O Gosebruch||Insider||Sell||18,000||$70.09||$1,261,620.00||96,074|| |
|6/14/2017||Carlos Alban||EVP||Sell||45,800||$70.00||$3,206,000.00||160,545|| |
|6/14/2017||Laura J Schumacher||Insider||Sell||79,800||$70.00||$5,586,000.00||187,625|| |
|5/19/2017||Richard A Gonzalez||Chairman||Sell||71,235||$65.49||$4,665,180.15||349,462|| |
|5/18/2017||William J Chase||CFO||Sell||38,300||$65.35||$2,502,905.00||209,043|| |
|5/4/2017||Carlos Alban||EVP||Sell||43,000||$67.00||$2,881,000.00||114,745|| |
|3/10/2017||Laura J Schumacher||Insider||Sell||40,000||$65.26||$2,610,400.00||147,415|| |
|3/10/2017||Robert A Michael||VP||Sell||5,132||$65.29||$335,068.28||16,706|| |
|3/10/2017||Timothy J Richmond||SVP||Sell||22,451||$65.29||$1,465,825.79||26,078|| |
|3/8/2017||Richard A Gonzalez||Chairman||Sell||72,016||$64.25||$4,627,028.00||369,113|| |
|12/2/2016||William J Chase||CFO||Sell||6,600||$59.19||$390,654.00||178,970|| |
|9/7/2016||Laura J Schumacher||Insider||Sell||50,000||$65.00||$3,250,000.00||144,138|| |
|6/24/2016||Laura J Schumacher||EVP||Sell||186,106||$60.03||$11,171,943.18||260,438|| |
|6/2/2016||Richard A Gonzalez||CEO||Sell||285,953||$63.82||$18,249,520.46||624,374|| |
|5/11/2016||Richard A Gonzalez||CEO||Sell||39,000||$63.80||$2,488,200.00||338,421|| |
|5/10/2016||Carlos Alban||EVP||Sell||47,438||$63.52||$3,013,261.76||149,444|| |
|5/10/2016||Thomas A Hurwich||VP||Sell||6,000||$63.59||$381,540.00||68,204|| |
|5/10/2016||Timothy J Richmond||SVP||Sell||21,583||$63.52||$1,370,952.16||44,615|| |
|3/8/2016||Laura J Schumacher||EVP||Sell||25,000||$56.09||$1,402,250.00||199,238|| |
|3/1/2016||Timothy J Richmond||SVP||Sell||12,866||$55.05||$708,273.30||79,064|| |
|4/28/2015||Richard A Gonzalez||CEO||Sell||102,964||$64.67||$6,658,681.88|| |
|3/2/2015||Laura J Schumacher||EVP||Sell||25,000||$60.30||$1,507,500.00|| |
|3/2/2015||Timothy J Richmond||SVP||Sell||14,388||$60.33||$868,028.04|| |
|12/22/2014||William J Chase||CFO||Sell||8,495||$68.00||$577,660.00|| |
|3/4/2014||Richard Gonzalez||CEO||Sell||4,799||$51.20||$245,708.80||395,403|| |
|3/3/2014||Azita Saleki-Gerhardt||SVP||Sell||2,443||$50.25||$122,760.75||85,828|| |
|3/3/2014||Carlos Alban||EVP||Sell||2,882||$50.09||$144,359.38||205,138|| |
|3/3/2014||William Chase||CFO||Sell||3,948||$50.22||$198,268.56||180,068|| |
|9/17/2013||Azita Saleki-Gerhardt||SVP||Sell||10,473||$45.84||$480,082.32||66,703|| |
|8/19/2013||Azita Saleki-Gerhardt||SVP||Sell||1,270||$43.01||$54,622.70||64,279|| |
|8/12/2013||Azita Saleki-Gerhardt||SVP||Sell||8,851||$44.91||$397,498.41||64,237|| |
|3/11/2013||Edward J Rapp||Director||Buy||2,500||$37.67||$94,175.00|| |
|2/4/2013||Frederick H Waddell||Director||Buy||2,000||$37.05||$74,100.00|| |
AbbVie (NYSE ABBV) News Headlines
AbbVie (NYSE:ABBV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement
AbbVie (NYSE ABBV) Stock Chart for Tuesday, January, 16, 2018